PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response

PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response

The epidermal growth factor receptor variant III (EGFRvIII) has been investigated as a therapeutic target for chimeric antigen receptor (CAR) T cell therapy in glioblastoma. Earlier research demonstrated that phenotypic and genotypic characteristics in T cells and CAR T product predicted therapeutic...

Full description

Bibliographic Details
Main Authors: Oliver Y. Tang, Lifeng Tian, Todd Yoder, Rong Xu, Irina Kulikovskaya, Minnal Gupta, Jan Joseph Melenhorst, Simon F. Lacey, Donald M. O’Rourke, Zev A. Binder
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Immunology
Subjects:
GBM
glioblastoma
CAR T cells
immunotherapy
PD-1
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.872756/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.872756/full

Similar Items